A multi‐institutional retrospective study of carbon‐ion radiotherapy for non‐squamous cell malignant tumors of the nasopharynx: Subanalysis of Japan Carbon‐Ion Radiation Oncology Study Group study 1402 HN

Abe, Takanori; Ohno, Tatsuya; Koto, Masashi; Demizu, Yusuke; Suefuji, Hiroaki; Tsuji, Hiroshi; Okimoto, Tomoaki; Shioyama, Yoshiyuki; Saitoh, Jun‐ichi; Shirai, Katsuyuki; Nemoto, Kenji; Nakano, Takashi; Kamada, Tadashi

doi:10.1002/cam4.1884

Cited by 19 publications

(21 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results indicated the safety of the combined treatment, and patients with macroscopically complete resection and gross residual tumors had similar toxicities. Ten articles (13)(14)(15)(16)(17)(18)(19)(20)(21)(22) were published from PBRT centers in Japan based on their registered studies, and most were retrospective. The studies were registered on UMIN-CTR shortly before the publication of the papers (date of registration in relation to publication not shown in our analysis).…”

Section: Discussionmentioning

confidence: 99%

A cross-sectional analysis of registered clinical trials on the use of particle beam radiation therapy in head and neck cancers

Zhang¹,

Kong²,

Lu³

2022

Ann Transl Med

View full text Add to dashboard Cite

Background: To present and analyze the current status of registered clinical trials on particle beam (including proton and carbon ion beam) radiation therapy (PBRT) for head and neck (H&N) malignancies, and to provide insights for future clinical research, we designed the cross-sectional analysis.Methods: We identified and analyzed all clinical trials of interest registered on ClinicalTrials.gov and PTCOG.ch until March 22, 2020.Results: We identified 57 registered clinical trials related to the use of proton therapy or carbon ion radiation therapy (CIRT) in H&N malignancies. There were 20, 27, and 5 trials focused on CIRT, proton therapy, and both ions, respectively. The eligible trials were registered between 2007 and 2020, mainly focused on adenoid cystic carcinoma (ACC), squamous cell carcinoma (SCC), sinonasal malignancies (SNM), skull base tumors, locally advanced, and recurrent tumors. The nature of 23 (40%) trials were not stated and could not be identified. A total of 25 (44%) registered trials were phase II, including randomized controlled trials (RCTs). There were 14 RCTs (7 phase II, 2 phase II/III, 2 phase III, 1 phase I/II, and 2 phase not applicable), and 25 studies including RCTs were registered before the first enrolment. There were 11 completed clinical trials among the eligible trials, including 7 with published trial-related results.Conclusions: Less than 10% of the countries with PBRT treatment facilities in operation have initiated clinical trials on H&N cancer. Furthermore, among all registered trials, less than 10% have been completed with results published. More clinical trials, especially high quality trials, are needed for optimizing and standardizing treatment techniques of PBRT for H&N malignancies.

show abstract

Section: Discussionmentioning

confidence: 99%

A cross-sectional analysis of registered clinical trials on the use of particle beam radiation therapy in head and neck cancers

Zhang¹,

Kong²,

Lu³

2022

Ann Transl Med

View full text Add to dashboard Cite

show abstract

“…The grade 3 or higher toxicity rate was 15%, with 2 patients experiencing a grade-5 pharyngeal hemorrhage [ 33 ]. In 2018, Abe et al [ 34 ] followed with a subgroup analysis of nasopharyngeal disease, including 29 ACCs and 7 MMs treated with 64 GyRBE; 2-year LC was 88%, with 1 grade-4 optic nerve and 2 grade-5 pharyngeal hemorrhages. Ikawa et al [ 35 ] conducted a histologic analysis for solid growth pattern H&NACC, finding no difference in LC between subtypes, though there were differences in OS and PFS.…”

Section: Adenoid Cystic Carcinomamentioning

confidence: 99%

The Role of Particle Therapy in Adenoid Cystic Carcinoma and Mucosal Melanoma of the Head and Neck

Ebner

Malouff

Frank

et al. 2021

International Journal of Particle Therapy

Self Cite

View full text Add to dashboard Cite

Particle irradiation is suitable for resistant histologies owing to a combination of improved dose delivery with potential radiobiologic advantages in high linear energy transfer radiation. Within the head and neck, adenoid cystic carcinoma and mucosal melanoma are two such histologies, being radioresistant and lying closely proximal to critical structures. Here, we review the use of particle irradiation for adenoid cystic carcinoma and mucosal melanoma of the head and neck.

show abstract

“…The pioneering investigations at LBNL showed that fractionated delivery of heavy ion therapy, generally as a boost at relatively low doses, was well tolerated across diverse tumor sites, including locally advanced prostate cancer, bone and soft tissue sarcomas, and head and neck tumors of the salivary gland and paranasal sinus . Subsequent phase I/II trials conducted largely in Japan and Germany employing higher doses and conducted primarily solely with CIRT have demonstrated negligible toxicity and encouraging tumor control rates in diverse histologic tumor types, including adenocarcinoma, adenoid cystic carcinoma, malignant melanoma, and bone and soft tissue sarcomas, tumors which are often resistant to conventional photon irradiation . Additional difficult to treat tumor sites with early favorable outcomes include tumors of the lung, liver, and pancreas.…”

Section: Opening Statementsmentioning

confidence: 99%

Three discipline collaborative radiation therapy (3DCRT) special debate: The United States needs at least one carbon ion facility

Blakely

Faddegon

Tinkle

et al. 2019

J Applied Clin Med Phys

View full text Add to dashboard Cite

Three discipline collaborative radiation therapy (3DCRT) special debate: The United States needs at least one carbon ion facility 1 | THREE DISCIPLINE COLLABORATIVE RAD IATION THERAPY (3DCRT) DEBATE SERIESRadiation oncology is a highly multidisciplinary medical specialty, drawing significantly from three scientific disciplinesmedicine, physics, and biology. As a result, discussion of controversies or changes in practice within radiation oncology involves input from all three disciplines. For this reason, significant effort has been expended recently to foster collaborative multidisciplinary research in radiation oncology, with substantial demonstrated benefit.( 1,2 ) In light of these results, we endeavor here to adopt this "team-science" approach to the traditional debates featured in this journal. This article is part of a series of special debates entitled "Three Discipline Collaborative Radiation Therapy (3DCRT)" in which each debate team will include a radiation oncologist, medical physicist, and radiobiologist. We hope that this format will not only be engaging for the readership but will also foster further collaboration in the science and clinical practice of radiation oncology. Dominello serves as the Assistant Program Director for the RadiationOncology Residency Program and as an instructor in courses for both graduate and undergraduate students at the university. Dr.Griffin is a professor of radiation biology at the University of Arkansas for Medical Sciences. His group studies living tissue response to high-dose radiotherapy (SBRT) and spatially fractionated radiation approaches with targeted drug delivery to tumors. He served as a ---

show abstract

A multi‐institutional retrospective study of carbon‐ion radiotherapy for non‐squamous cell malignant tumors of the nasopharynx: Subanalysis of Japan Carbon‐Ion Radiation Oncology Study Group study 1402 HN

Cited by 19 publications

References 27 publications

A cross-sectional analysis of registered clinical trials on the use of particle beam radiation therapy in head and neck cancers

A cross-sectional analysis of registered clinical trials on the use of particle beam radiation therapy in head and neck cancers

The Role of Particle Therapy in Adenoid Cystic Carcinoma and Mucosal Melanoma of the Head and Neck

Three discipline collaborative radiation therapy (3DCRT) special debate: The United States needs at least one carbon ion facility

Contact Info

Product

Resources

About